PR Newswire
NEW YORK, Nov. 17, 2020
NEW YORK , Nov. 17, 2020 /PRNewswire/ -- Relmada Therapeutics, Inc. (Nasdaq: RLMD), a clinical-stage company developing novel therapies for the treatment of central nervous system (CNS) diseases, today announced that Sergio Traversa , Chief Executive Officer of Relmada, will participate in the following upcoming virtual investor conferences:
Jefferies London Healthcare Conference
Date: Thursday, November 19, 2020
Time: 10:50 AM EST / 3:50 PM GMT
Webcast: A live webcast of the fireside chat will be available by visiting the "Investors" section of the company's website: www.relmada.com . A replay of the webcast will be available for 90 days following the conclusion of the live presentation broadcast.
Piper Sandler 32 nd Annual Healthcare Conference
Management will participate in a fireside chat, which will be accessible beginning on November 23, 2020 , via the "Investors" section of the company's website: www.relmada.com . The link will remain active for 90 days thereafter.
About Relmada Therapeutics, Inc.
Relmada Therapeutics is a late-stage pharmaceutical company addressing diseases of the central nervous system (CNS), with a focus on major depressive disorder (MDD). Our experienced and dedicated team is committed to making a difference in the lives of patients and their families. Relmada' s lead program, REL-1017, is a novel NMDA receptor (NMDAR) channel blocker that preferentially targets hyperactive channels while maintaining physiological glutamatergic neurotransmission, and is entering late-stage studies as an adjunctive treatment for MDD in adults.
Investor Contact:
Tim McCarthy
LifeSci Advisors
212-915-2564
tim@lifesciadvisors.com
Media Inquiries:
FischTank PR
relmada@fischtankpr.com
SOURCE Relmada Therapeutics, Inc.